Oral Lopinavir–Ritonavir for Severe Covid-19 Investigators in China report the results of an open-label, randomized clinical trial of lopinavir–ritonavir for the treatment of Covid-19 in 199 These interim trial results show that hydroxychloroquine and
In this study, chloroquine and lopinavir/ritonavir tablets were used to treat patients with
Recent clinical evidence didn't confirm the beneficial role of lopinavir/ritonavir and
DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i
However, lopinavir/ritonavir showed better efficacy than arbidol for the same outcomes (P<0
Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2
Participants in both groups were comparable at baseline for the age, gender, ethnicity, comorbid conditions and requirement of respiratory support
A synergy between ritonavir-boosted lopinavir (LPVr), ivermectin, and chloroquine was suggested to improve COVID-19 treatment
Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients
2,3
Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted
On January 31, the first two COVID-19 cases in Russia were confirmed by Russian Ministry of Health
Safety
In children 10 to < 14 kg who can swallow the tablets whole, administer two 100/25 mg tablets in the morning and one 100/25 mg tablet in the evening (daily dose: 300/75 mg)
In one limited sample sized RCT, chloroquine (CQ) administration was associated with better virological cure and the percentage of patients becoming “SARS-CoV-2 negative” were slightly higher (day 7, 10, and 14)
The effectiveness of lopinavir/ritonavir (LPV/r) and chloroquine treatment for COVID-19 has not been verified
Mean apparent oral clearance was 0
However, there were other factors such as acute renal failure and critical illness (case‐1)